medigraphic.com
Revista Médica Sinergia

2021, Number 02

<< Back Next >>

Revista Médica Sinergia 2021; 6 (02)

The impact of the microbiota on cardiovascular disease

Álvarez VM, Cortés BMV, Quirós MLM

Language: Spanish
References: 35
Page: 1-12
PDF size: 259.30 Kb.


ABSTRACT

The term "microbiota" refers to the ecosystem of microorganisms that colonizes the gastrointestinal tract. Its main functions are nutrition, metabolism, defense and works traffic. It is influenced by both internal and external factors. Dysbiosis is the alteration of the intestinal microbiota and its relationship with the host and has recently been associated with cardiovascular disease. It has been confirmed that the microbiota increases cardiovascular risk by different mechanisms, mainly due to an increase in body fat, an increase in oxidative stress, the production of metabolic toxins and systemic inflammation. Diet, being one of the main modules of bacterial strains, represents a promising therapeutic and preventive objective, as well as other therapies under study.


REFERENCES

  1. Susan V. Lynch, Ph.D. “The Human Intestinal Microbiome in Health and Disease”. The New England Journal of Medicine, December 15, 2016. https://www.nejm.org/doi/full/10.1056/NEJMra1600266

  2. Teresa Alarcón Cavero, Giuseppe D’Auria, Susana Delgado Palacio, “Microbiota Humana”, Elsevier, 2018. https://www.sciencedirect.com/science/article/abs/pii/S2529993X18300522

  3. Alexander Swidsinski, MDVera Loening-Baucke, MD. “Spatial organization of intestinal microbiota in health and disease”. Up to Date, Aug 2020. https://www.uptodate.com.ezproxy.ucimed.com/contents/spatial-organization-ofintestinal- microbiota-in-health-anddisease? search=microbiota%20intestinal&source=search_result&selectedTitle=1~150&usage_type=default&dis play_rank=1

  4. Reynaldo de Jesús Michel Aceves, Ana Celia Izeta Gutiérrez, Gabriela Torres Alarcón, Ana Celia Margarita Michel Izeta. “La microbiota y el microbioma intestinal humano”Medigraphic, Vol. 71 • Núm. 5 Septiembre-Octubre • 2017. https://www.medigraphic.com/pdfs/sanmil/sm-2017/sm175g.pdf

  5. Maria Carlota Dao, Karine Clément. “Gut microbiota and obesity: Concepts relevant to clinical care”. European Journal Internacional Medicine, October 27, 2017”. https://pubmed.ncbi.nlm.nih.gov/29110901/ G

  6. Kuramitsu HK, He X, Lux R. “Interspecies interactions within oral microbial communities”. Microbiol Mol Biol Rev, 2017; 71:653. https://doi.org/10.1128/MMBR.00024-07

  7. Hongyang Yao, Chaonan Fan, Yuanyuan Lu, Xiuqin Fan, Lulu Xia, Ping Li, Rui Wang, Tiantian Tang, Yuanyuan Wang, Kemin Qi. “Alteration of gut microbiota affects expression of adiponectin and resistin through modifying DNA methylation in high-fat diet-induced obese mice”. Genes & Nutrition, 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318443/

  8. Tine Jess, M.D. “Microbiota, Antibiotics, and Obesity”. The New England Journal of Medicine, December 25, 2014,371:2526-2528. https://doi.org/10.1056/NEJMcibr1409799

  9. Organización panamericana de la salud, OPS, “Riesgo Cardiovascular”. 2020. https://www.paho.org/cardioapp/web/

  10. Organización Mundial de la Salud. OMS, Obesidad y sobrepeso. 2020. http://www.who.int/mediacentre/factsheets/fs311/es/.

  11. M.E. Icaza-Chávez. “Microbiota intestinal en la salud y la enfermedad. Gut microbiota in health and disease", Revista de Gastroenterología de México, August 2015, Volume 78, Issue 4. https://doi.org/10.1016/j.rgmx.2013.04.004

  12. Dr. Lino Mayorga Reyes, Dr. Alejandro Azaola, “Impacto de la obesidad en la población y su relación con la microbiota intestinal”. Departamento de Sistemas Biológicos, Universidad Autónoma Metropolitana Unidad Xochimilco, México. vol.45 no.2, Junio 2016. http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S1870- 01952014000200002

  13. Elaine Patterson, Paul M Ryan, John F Cryan, Timothy G Dinan, R Paul Ross, Gerald F Fitzgerald, Catherine Stanton. “Gut microbiota, obesity and diabetes”. April 25, 2016 BMJ Jorunals. https://doi.org/10.1136/postgradmedj-2015-133285

  14. Manuel T. Velásquez, Patricia Centron, Ian Barrows, Rama Dwivedi and Dominic S. Raj. “Gut Microbiota and Cardiovascular Uremic Toxicities”, Pub Med, 2018 Jul; 10 (7). https://doi.org/10.3390/toxins10070287

  15. Zhang L.S., Davies S.S. “Microbial metabolism of dietary components to bioactive metabolites: Opportunities for new therapeutic interventions.” Genome Med. 2016; 8:46. https://doi.org/10.1186/s13073-016-0296-x

  16. Elaine Patterson, Paul M Ryan, John F Cryan, Timothy G Dinan, R Paul Ross, Gerald F Fitzgerald, Catherine Stanton. “Gut microbiota, obesity and diabetes”. BMJ Journals, April 25, 2016.,https://doi.org/10.1136/postgradmedj-2015-133285

  17. Fernández-Prado R, Esteras R., Perez-Gomez M.V, Gracia-Iguacel C, González-Parra E, Sanz A.B, Ortiz A, Sanchez-Niño M.D. “Nutrients turned into toxins: Microbiota modulation of nutrient properties in chronic kidney disease”. Nutrients. 2017; 9:489. https://doi.org/10.3390/nu9050489

  18. Takeshi Kitai, W. H. Wilson Tang, Gut microbiota in cardiovacular disease and heart failure. Clin SciUS national library of medicine PMC,2018 Jan 16; 132(1): 85–91. https://doi.org/10.1042/CS20171090

  19. Raúl Fernández Prado, Raquel Esteras, Nutrients Turned into Toxins: Microbiota Modulation of Nutrient Properties in Chronic Kidney Disease, May 2017 Nutrients 9. https://doi.org/10.3390/nu9050489

  20. W. H. Wilson Tang, Fredrik Backhed, Ulf Landmesser, Stanley L. HazenIntestinal. “Microbiota in Cardiovascular Health and Disease”. JACC State-of-the-Art Review PMC 2020 Apr 30. Apr 30; 73 (16). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518422/

  21. Ofelia Uzcátegui U. “Microbioma humano” Unidad de Investigación de Aparato Digestivo. Hospital Universitario. Venezuela, 2016. http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0048-77322016000100001

  22. Methe B, Karen N, Mihai P, Heather HC, Mitchelle GG, Curtis H, et al. NIH Public Acces. A framework for human microbiome research. Revisado en diciembre 2015. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377744/

  23. Takeshi Kitaia, W.H. Wilson Tang, Impacto de la microbiota intestinal en la enfermedad cardiovascular, Vol. 70. Núm. 10., revista española de cardiología. páginas 799-800 (Octubre 2017). https://doi.org/10.1016/j.recesp.2017.04.003

  24. W.H. Wilson Tang, Zeneng Wang, Bruce S. Levison, Robert A. Koeth, Earl B. Britt, Xiaoming Fu, Yuping Wu, and Stanley L. Hazen. “Intestinal Microbial Metabolism of Phosphatidylcholine and Cardiovascular Risk”. The New England Journal of Medicine, april 2018 vol. 368. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1109400

  25. Joao Marcus Oliveira Andrade, Deborah de Farias Lelis. “Angiotensin Converting Enzyme 2 (ACE2), Gut Microbiota, and Cardiovascular Health”, Pubmed, 2017 Nov 17;24(9):827-832. https://doi.org/10.2174/0929866524666170728145333

  26. Daniel Martín Frutos, El impacto de la microbiota en la enfermedad cardiovascular, Universidad de Valladolid, 2018. https://core.ac.uk/download/pdf/222807758.pdf

  27. Alina Mihaela Leustean, Manuela Ciocoiu, Anca Sava, Claudia Florida Costea, Mariana Floria, Claudia Cristina Tarniceriu,Daniela Maria Tanase. “Implications of the Intestinal Microbiota in Diagnosing the Progression of Diabetes and the Presence of Cardiovascular Complications”, J Diabetes Res. 2018. https://doi.org/10.1155/2018/5205126

  28. Fengwei Pan, Liying Zhang, Min Li, Yingxin Hu,Benhua Zeng, Huijuan Yuan, Liping Zhao, Chenhong Zhang. “Predominant gut Lactobacillus murinus strain mediates anti-inflammaging effects in calorie-restricted mice”, Microbiome. 2018; 6: 54. https://doi.org/10.1186/s40168-018-0440-5

  29. Zeneng Wang, Yongzhong Zhao. “Gut microbiota derived metabolites in cardiovascular health and disease” Protein Cell. 2018 May; 9(5): 416-431. https://doi.org/10.1007/s13238-018-0549-0

  30. Maria Carlota Dao, Karine Clément. “Gut microbiota and obesity: Concepts relevant to clinical care” European Federation of Internal Medicine. 2017. https://pubmed.ncbi.nlm.nih.gov/29110901/

  31. Luis Vitetta, Jeremy D Henson. “Probiotics and synbiotics targeting the intestinal microbiome attenuate nonalcoholic fatty liver disease”, Pub Med, 2020Aug (9) 526-529. https://doi.org/10.21037/hbsn.2019.11.24

  32. Maria Jose Sáez-Lara, Cándido Robles-Sánchez, Francisco Javier Ruiz-Ojeda, Julio Plaza-Díaz , Angel Gil. “Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials”. Pub Med,2016, 13:17. https://doi.org/10.3390/ijms17060928

  33. R Balfour Sartor, MD, “Probiotics for gastrointestinal diseases”, Up to Date, Sep 01, 2020. https://www.uptodate.com.ezproxy.ucimed.com/contents/probiotics-for-gastrointestinaldiseasessearch= microbiota&source=search_result&selectedTitle=2~117&usage_type=default&display_rank=2

  34. Rafael Tojo González, Adolfo Suárez González. “Papel de la microbiota y probiótico-terapia. Nutrition Hospitalaria” Nutr Hosp. 2015;31(Supl. 1):83-88. http://www.aulamedica.es/nh/pdf/8713.pdf

  35. García-Guerrero, Jair. “Probióticos como terapia integrada de trastornos digestivos”. Hospital Christus - Muguerza Alta Especialidad (2018). https://www.researchgate.net/publication/324731282_Probioticos_como_terapia_integrada_de_trastornos_diges tivos/citation/download




2020     |     www.medigraphic.com